Pascolizumab
Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma has been conducted in 2001/2002.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IL-4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
  | |
References
- Hart, TK; Blackburn, MN; Brigham-Burke, M; Dede, K; Al-Mahdi, N; Zia-Amirhosseini, P; Cook, RM (2002). "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma". Clinical and Experimental Immunology. 130 (1): 93–100. doi:10.1046/j.1365-2249.2002.01973.x. PMC 1906490. PMID 12296858.
- ClinicalTrials.gov
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
Interleukin receptor modulators | |||||
|---|---|---|---|---|---|
| IL-1 |
| ||||
| IL-2 |
| ||||
| IL-3 |
| ||||
| IL-4 |
| ||||
| IL-5 |
| ||||
| IL-6 |
| ||||
| IL-7 |
| ||||
| IL-8 |
| ||||
| IL-9 |
| ||||
| IL-10 |
| ||||
| IL-11 |
| ||||
| IL-12 |
| ||||
| IL-13 |
| ||||
| IL-15 |
| ||||
| IL-17 |
| ||||
| IL-18 |
| ||||
| IL-20 |
| ||||
| IL-21 |
| ||||
| IL-22 |
| ||||
| IL-23 |
| ||||
| IL-27 |
| ||||
| IL-28 |
| ||||
| IL-31 |
| ||||
| IL1RL1 |
| ||||
| IL1RL2 |
| ||||
| Others |
| ||||
| |||||
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.